share_log

Jefferies Downgrades Beam Therapeutics to Hold, Lowers Price Target to $30

Jefferies Downgrades Beam Therapeutics to Hold, Lowers Price Target to $30

杰富瑞将Beam Therapeutics的评级下调至持有,将目标股价下调至30美元
Benzinga ·  2023/12/08 06:56

Jefferies analyst Michael Yee downgrades Beam Therapeutics (NASDAQ:BEAM) from Buy to Hold and lowers the price target from $75 to $30.

杰富瑞分析师迈克尔·伊将Beam Therapeutics(纳斯达克股票代码:BEAM)的评级从买入下调至持有,并将目标股价从75美元下调至30美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发